Skip to main content
Publications
Hoffman V, Hallas J, Linder M, Margulis AV , Suehs BT, Arana A , Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD. Cardiovascular risk in users of mirabegron relative to users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, real-world data safety study . Presented at the Virtual ICPE 2021 Conference; August 24, 2021. Previously presented at the 2020 Virtual American Heart Association’s Scientific Sessions.
Hoffman V , Hallas J, Linder M, Margulis AV , Suehs BT, Arana A , Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD, mirabegron PMR-PASS study group. Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study . Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7
Phiri K, Hallas J, Linder M, Margulis A , Suehs B, Arana A , Bahmanyar S, Hoffman V , Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Kristiansen NS, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder . Curr Med Res Opin. 2021 May;37(5):867-77. doi: 10.1080/03007995.2021.1891035
Arana A , Margulis AV , Varas-Lorenzo C, Bui CL , Gilsenan A , McQuay LJ, Reynolds M , Rebordosa C , Franks B, de Vogel S, Appenteng K, Perez-Gutthann S . Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom . Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150